Difference between revisions of "Epithelioid sarcoma"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "https://clinicaltrials.gov/ct2/show/[https://clinicaltrials.gov/ct2/show/" to "https://clinicaltrials.gov/ct2/show/") |
Warner-admin (talk | contribs) m (Text replacement - "clinicaltrials.gov/ct2/show" to "clinicaltrials.gov/study") |
||
| Line 46: | Line 46: | ||
</div></div> | </div></div> | ||
===References=== | ===References=== | ||
| − | <!-- # '''Abstract:''' Mrinal M. Gounder, Silvia Stacchiotti, Patrick Schöffski, Steven Attia, Antoine Italiano, Robin Jones, George D. Demetri, Stephen Blakemore, Alicia Clawson, Scott Daigle, Scott Ribich, Maria Roche, Jill Rodstrom, Peter T.C. Ho, and Gregory Michael Cote. Phase 2 multicenter study of the EZH2 inhibitor tazemetostat in adults with INI1 negative epithelioid sarcoma ([https://clinicaltrials.gov/ | + | <!-- # '''Abstract:''' Mrinal M. Gounder, Silvia Stacchiotti, Patrick Schöffski, Steven Attia, Antoine Italiano, Robin Jones, George D. Demetri, Stephen Blakemore, Alicia Clawson, Scott Daigle, Scott Ribich, Maria Roche, Jill Rodstrom, Peter T.C. Ho, and Gregory Michael Cote. Phase 2 multicenter study of the EZH2 inhibitor tazemetostat in adults with INI1 negative epithelioid sarcoma ([https://clinicaltrials.gov/study/NCT02601950 Clinical Trial Registry]). Journal of Clinical Oncology 2017 35:15_suppl, 11058-11058. [https://doi.org/10.1200/JCO.2017.35.15_suppl.11058 link to abstract] [https://clinicaltrials.gov/study/NCT02601950 Clinical Trial Registry] CT.gov] --> |
| − | # '''EZH-202:''' Gounder M, Schöffski P, Jones RL, Agulnik M, Cote GM, Villalobos VM, Attia S, Chugh R, Chen TW, Jahan T, Loggers ET, Gupta A, Italiano A, Demetri GD, Ratan R, Davis LE, Mir O, Dileo P, Van Tine BA, Pressey JG, Lingaraj T, Rajarethinam A, Sierra L, Agarwal S, Stacchiotti S. Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study. Lancet Oncol. 2020 Nov;21(11):1423-1432. Epub 2020 Oct 6. [https://doi.org/10.1016/s1470-2045(20)30451-4 link to original article] '''contains dosing details in abstract''' [https://pubmed.ncbi.nlm.nih.gov/33035459/ PubMed] [https://clinicaltrials.gov/ | + | # '''EZH-202:''' Gounder M, Schöffski P, Jones RL, Agulnik M, Cote GM, Villalobos VM, Attia S, Chugh R, Chen TW, Jahan T, Loggers ET, Gupta A, Italiano A, Demetri GD, Ratan R, Davis LE, Mir O, Dileo P, Van Tine BA, Pressey JG, Lingaraj T, Rajarethinam A, Sierra L, Agarwal S, Stacchiotti S. Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study. Lancet Oncol. 2020 Nov;21(11):1423-1432. Epub 2020 Oct 6. [https://doi.org/10.1016/s1470-2045(20)30451-4 link to original article] '''contains dosing details in abstract''' [https://pubmed.ncbi.nlm.nih.gov/33035459/ PubMed] [https://clinicaltrials.gov/study/NCT02601950 Clinical Trial Registry] |
[[Category:Epithelioid sarcoma regimens]] | [[Category:Epithelioid sarcoma regimens]] | ||
Revision as of 01:42, 25 June 2023
Section editor transclusions Note: these are regimens tested in subtype-specific populations, please see the main soft tissue sarcoma page for other regimens.
1 regimens on this page
1 variants on this page
|
All lines of therapy
Tazemetostat monotherapy
Regimen
| FDA-recommended dose |
| Study | Dates of enrollment | Evidence | |
|---|---|---|---|
Gounder et al. 2020 (EZH-202)
|
2015-2017 | Phase 2 (RT) |
Biomarker eligibility criteria
One or both of the following:
- Loss of INI1 expression by IHC
- Biallelic SMARCB1 alterations
References
- EZH-202: Gounder M, Schöffski P, Jones RL, Agulnik M, Cote GM, Villalobos VM, Attia S, Chugh R, Chen TW, Jahan T, Loggers ET, Gupta A, Italiano A, Demetri GD, Ratan R, Davis LE, Mir O, Dileo P, Van Tine BA, Pressey JG, Lingaraj T, Rajarethinam A, Sierra L, Agarwal S, Stacchiotti S. Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study. Lancet Oncol. 2020 Nov;21(11):1423-1432. Epub 2020 Oct 6. link to original article contains dosing details in abstract PubMed Clinical Trial Registry